The Maharashtra government has invited Amazon to expand its investments
Union Health Minister Jagat Prakash Nadda has launched the Unified
Gurugram Research Institute Achieves Breakthrough in Treating Children with Sickle Cell Disease
In a significant medical advancement, researchers at a Gurugram-based institute have reported a major breakthrough in the treatment of children suffering from Sickle Cell
Lilly Announces Over $1 Billion Investment in New Contract Manufacturing in India
Investment to expand manufacturing and global medicine supply capacity — resonating with the Make in India agenda Eli Lilly and Company today announced plans to
World Immunization Day : Why Adult Immunization Matters?
Kolkata, 10th November: World Immunisation Day is observed on 10th November every year, and the theme this year is ‘Immunisation for All is Humanly
VASKAR Walkathon 2025: “Amputation-Free India” Marches Strong from Freedom Park to Vidhana Soudha
The Vascular Surgeons Association of Karnataka (VASKAR) organized the Walkathon 2025 today in Bengaluru under the inspiring theme “Amputation-Free India.” Over 500 doctors, vascular specialists, and paramedical professionals came together
Dementia India Alliance and Apollo AyurVAID Hospitals sign MoU to Advance Integrative Dementia Care and Awareness
Dementia India Alliance (DIA), a national, NGO dedicated to promoting awareness, advocacy, and care for people living with dementia, and Apollo AyurVAID Hospitals, India’s
Andhra Pradesh CM Chandrababu Naidu Inaugurates New Block at Sankara Super Speciality Eye Hospital in Pedakakani, Guntur
This world-class eye care facility has been built at an investment of around Rs 75 crore. With this expansion, Sankara Eye Hospital, Pedakakani,
Syngene Results Q2 FY26
Second quarter revenue from operations grows 4% sequentially and 2% year-on-year to Rs. 911 Cr 1st half revenue from operations up 6% Syngene International Limited today announced financial results for the second quarter and half year of FY26. Quarterly Financial Highlights (All numbers are in Indian Rupees in Cr except margins) Q2 FY25 Q2 FY26 YoY Change (%) Revenue from Operations 891 911 2% Reported Revenue 908 926 2% Reported EBITDA 261 215 -18% Reported EBITDA margin (%) 28.8% 23.2% Reported PAT (before exceptional items) 106 67 -37% Reported PAT Margin (%) 11.7% 7.3% H1 FY26 Financial Highlights (All numbers are in Indian rupees in Crores except margins) H1 FY25 H1 FY26 YoY Change (%) Revenue from Operations 1,681 1,785 6% Reported Revenue 1,715 1,818 6% Reported EBITDA 449 439 -2% Reported EBITDA margin (%) 26.2% 24.1% Reported PAT (before exceptional items) 161* 154 -4% Reported PAT Margin (%) 9.4% 8.5% Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim. Commenting on
VENUS REMEDIES EXPANDS EXPORTS PORTFOLIO IN ASEAN WITH NEW MARKETING AUTHORISATIONS IN VIETNAM
The approvals strengthen India’s position as a reliable supplier of advanced pharmaceuticals across ASEAN markets where Venus Remedies already exports more than 374 products. Venus
